Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol

Pharmacogenomics Journal

Volumn 17, Issue 1, 2017, Pages 4-10

  Franca, R ^a   Rebora, P ^b   Bertorello, N ^c   Fagioli, F ^c   Conter, V ^d   Biondi, A ^d   Colombini, A ^d   Micalizzi, C ^e   Zecca, M ^f   Parasole, R ^g   Petruzziello, F ^g   Basso, G ^h   Putti, M C ^h   Locatelli, F ⁱ   D'Adamo, P ^a   Valsecchi, M G ^b   Decorti, G ^j   Rabusin, M ^a  

^a INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^d SAN GERARDO HOSPITAL   (Italy)

^e G GASLINI INSTITUTE   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g SANTOBONO PAUSILIPON CHILDREN S HOSPITAL   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ UNIVERSITY OF PAVIA   (Italy)

^j UNIVERSITY OF TRIESTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE; ADENOSINE A2A RECEPTOR; ANTINEOPLASTIC AGENT; GLUTATHIONE S-TRANSFERASE M1; GLUTATHIONE S-TRANSFERASE T1; GLUTATHIONE TRANSFERASE; INORGANIC PYROPHOSPHATASE; ITPA PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ABCC1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADORA2A GENE; ARTICLE; CANCER CHEMOTHERAPY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL TOXICITY; GENE; GENE DELETION; GENETIC VARIABILITY; GENOTYPE; GST M1 GENE; GST T1 GENE; HOMOZYGOTE; HUMAN; ITPA GENE; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEUROTOXICITY; PEDIATRICS; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; ADVERSE EFFECTS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); CONSOLIDATION CHEMOTHERAPY; GASTROINTESTINAL DISEASE; GENETIC PREDISPOSITION; GENETICS; INDUCTION CHEMOTHERAPY; INFANT; METABOLISM; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NEUROLOGIC DISEASE; PATHOLOGY; PHARMACOGENETIC TESTING; PHARMACOGENETIC VARIANT; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE; PRESCHOOL CHILD; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CONSOLIDATION CHEMOTHERAPY; FEMALE; GASTROINTESTINAL DISEASES; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GLUTATHIONE TRANSFERASE; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; LOGISTIC MODELS; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MULTIPLEX POLYMERASE CHAIN REACTION; MUTATION; NERVOUS SYSTEM DISEASES; PHARMACOGENETICS; PHARMACOGENOMIC TESTING; PHARMACOGENOMIC VARIANTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDICTIVE VALUE OF TESTS; PYROPHOSPHATASES; RECEPTOR, ADENOSINE A2A; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84949580071     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.83     Document Type: Article

References (40)

1. Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010; 115: 3206-3214
2. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Moricke A et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011; 118: 2077-2084
3. Vecchi V, Arico M, Basso G, Ceci A, Madon E, Mandelli F et al. Risk-directed therapy for childhood acute lymphoblastic leukemia. Results of the Associazione Italiana Ematologia Oncologia Pediatrica '82 studies. Cancer 1993; 72: 2517-2524
4. AIRTUM Working GroupCCMAIEOP Working Group. Italian cancer figures, report 2012: Cancer in children and adolescents. Epidemiol Prev 37 (1 Suppl 1): 1-225
5. Gervasini G, Vagace JM. Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia. Front Genet 2012; 3: 249
6. Stocco G, Franca R, Verzegnassi F, Londero M, Rabusin M, Decorti G. Pharmacogenomic approaches for tailored anti-leukemic therapy in children. Curr Med Chem 2012; 20: 2237-2253
7. Franca R, Rebora P, Basso G, Biondi A, Cazzaniga G, Crovella S et al. Glutathione S-transferase homozygous deletions and relapse in childhood acute lymphoblastic leukemia: a novel study design in a large Italian AIEOP cohort. Pharmacogenomics 2012; 13: 1905-1916
8. Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 1997; 15: 1560-1566
9. Rizzari C, Putti MC, Colombini A, Casagranda S, Ferrari GM, Papayannidis C et al. Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment. Hematol Rep 2014; 6: 5554
10. Mikkelsen TS, Thorn CF, Yang JJ, Ulrich CM, French D, Zaza G et al. PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 2011; 21: 679-686
11. Hider SL, Thomson W, Mack LF, Armstrong DJ, Shadforth M, Bruce IN. Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology 2008; 47: 1156-1159
12. Li L, Agarwal S, Elmquist WF. Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos. 2013; 41: 659-667
13. Bleyer WA, Dedrick RL. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection. Cancer Treat Rep 1977; 61: 703-708
14. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414: 916-920
15. Kishi S, Cheng C, French D, Pei D, Das S, Cook EH et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109: 4151-4157
16. Heller T, Oellerich M, Armstrong VW, von Ahsen N. Rapid detection of ITPA 94C4A and IVS2+21A4C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2+21A4C polymorphism on splicing efficiency. Clin Chem 2004; 50: 2182-2184
17. Stocco G, Cheok MH, Crews KR, Dervieux T, French D, Pei D et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009; 85: 164-172
18. Adam Beaumais T, Fakhoury M, Medard Y, Azougagh S, Zhang D, Yakouben K et al. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br J Clin Pharmacol 2011; 71: 575-584
19. Kim H, Kang HJ, Kim HJ, Jang MK, Kim NH, Oh Y et al. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism. PLoS ONE 2012; 7: e45558
20. Wan Rosalina WR, Teh LK, Mohamad N, Nasir A, Yusoff R, Baba AA et al. Polymorphism of ITPA 94C4A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J Clin Pharm Ther 2012; 37: 237-241
21. Stocco G, Yang W, Crews KR, Thierfelder WE, Decorti G, Londero M et al. PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity. Hum Mol Genet 2012; 21: 4793-4804
22. Warren RB, Smith RL, Campalani E, Eyre S, Smith CH, Barker JN et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008; 128: 1925-1929
23. Soontornmalai A, Vlaming ML, Fritschy JM. Differential, strain-specific cellular and subcellular distribution of multidrug transporters in murine choroid plexus and blood-brain barrier. Neuroscience 2006; 138: 159-169
24. Kilic E, Spudich A, Kilic U, Rentsch KM, Vig R, Matter CM et al. ABCC1: a gateway for pharmacological compounds to the ischaemic brain. Brain 2008; 131: 2679-2689
25. Lamba J, Hebert JM, Schuetz EG, Klein TE, Altman RB. PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenet Genomics 2012; 22: 555-558
26. Aplenc R, Glatfelter W, Han P, Rappaport E, La M, Cnaan A et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol 2003; 122: 240-244
27. Moore AS, Norris R, Price G, Nguyen T, Ni M, George R et al. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limitedsampling, population modelling approach. J Paediatr Child Health 2011; 47: 875-882
28. Davies SM, Borowitz MJ, Rosner GL, Ritz K, Devidas M, Winick N et al. Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111: 2984-2990
29. Guha N, Chang JS, Chokkalingam AP, Wiemels JL, Smith MT, Buffler PA. NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol 2008; 168: 1221-1232
30. van Rossum EF, Koper JW, van den Beld AW, Uitterlinden AG, Arp P, Ester W et al. Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index. Clin Endocrinol 2003; 59: 585-592
31. Huizenga NA, Koper JW, De Lange P, Pols HA, Stolk RP, Burger H et al. A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab 1998; 83: 144-151
32. Cuzzoni E, Iudicibus S, Bartoli F, Ventura A, Decorti G. Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone. Br J Clin Pharmacol 2012; 73: 651-655
33. Marino S, Verzegnassi F, Tamaro P, Stocco G, Bartoli F, Decorti G et al. Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response. Pediatr Blood Cancer 2009; 53: 984-991
34. Lauten M, Matthias T, Stanulla M, Beger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes. Leukemia 2002; 16: 1437-1442
35. French D, Hamilton LH, Mattano LA Jr, Sather HN, Devidas M, Nachman JB et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111: 4496-4499
36. Stocco G, Crews KR, Evans WE. Genetic polymorphism of inosine-triphosphatepyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-Smethyl-transferase status. Expert Opin Drug Saf 2012; 9: 23-37
37. Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ et al. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics 2009; 19: 935-944
38. Kelly JL, Novak AJ, Fredericksen ZS, Liebow M, Ansell SM, Dogan A et al. Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2010; 19: 2847-2858
39. Huang RS, Duan S, Kistner EO, Bleibel WK, Delaney SM, Fackenthal DL et al. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 2008; 68: 3161-3168
40. Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero I, Colomer D, Perez-Alvarez S et al. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res 2008; 68: 10178-10186